Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 660 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Fourth Vaccine Dose Increases in Humoral Immunity Against Omicron Variants in... October 3, 2022 Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic... July 2, 2021 Eflornithine Plus Sulindac Not Superior to Either Drug Alone in FAP September 15, 2020 Cancer Research UK thanks Tania Bryer for a decade of fundraising... April 19, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Catumaxomab Inside Cancer Grand Challenges Part 1: what makes a grand challenge? ESMO Welcomes Launch of Health Package Introducing EU Measures That Can... Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With...
